Piramal Pharma has reported results for fourth quarter (Q4) and year ended March 31, 2023.
The company has reported 72.46% fall in its net profit at Rs 41.70 crore for the quarter under review as compared to Rs 151.44 crore for the same quarter in the previous year. Total income of the company decreased by 7.06% at Rs 1,117.46 crore for Q4FY23 as compared to Rs 1,202.38 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 75.44% fall in its net profit at Rs 50.11 crore for fourth quarter ended March 31, 2023 as compared to Rs 204.06 crore for the same quarter in the previous year. Total income of the company decreased by 0.97% at Rs 2,188.08 crore for Q4FY23 as compared to Rs 2,209.50 crore for the corresponding quarter previous year.
For the year ended March 31, 2023, the company has reported 81.09% fall in its net profit at Rs 69.50 crore as compared to Rs 367.54 crore for the previous year. However, total income of the company increased by 6.14% at Rs 3784.29 crore for year under review as compared to Rs 3,565.21 crore for year ended March 31, 2022.
For the year ended March 31, 2023, on the consolidated basis, the company has reported net loss of Rs 186.46 crore as compared to net profit of Rs 375.96 crore for the previous year. However, total income of the company increased by 6.90% at Rs 7,306.66 crore for year under review as compared to Rs 6,834.90 crore for year ended March 31, 2022.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |